The placental growth factor as a target against hepatocellular carcinoma in a diethylnitrosamine-induced mouse model

Journal of Hepatology

Volumn 58, Issue 2, 2013, Pages 319-328

  Heindryckx, Femke ^a   Coulon, Stephanie ^a   Terrie, Ellen ^a   Casteleyn, Christophe ^b   Stassen, Jean Marie ^c   Geerts, Anja ^a   Libbrecht, Louis ^a   Allemeersch, Joke ^d   Carmeliet, Peter ^d,e   Colle, Isabelle ^a   Van Vlierberghe, Hans ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c ThromboGenics NV   (Belgium)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^e UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Angiogenesis; Antiangiogenic treatment; Metastasis; PlGF; Sorafenib; Vascular normalisation; VEGF

Indexed keywords

DIETHYLNITROSAMINE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PLACENTAL GROWTH FACTOR; PLACENTAL GROWTH FACTOR; SORAFENIB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG TARGETING; GENE EXPRESSION; GENE EXPRESSION PROFILING; HYPOXIA; LIVER CELL CARCINOMA; METASTASIS INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DIETHYLNITROSAMINE; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; LIVER NEOPLASMS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; PHENYLUREA COMPOUNDS; PREGNANCY PROTEINS; TREATMENT OUTCOME;

EID: 84872418622     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.09.032     Document Type: Article

References (50)

1. M. Huang, and G. Liu The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line Cancer Lett 135 1999 97 105
2. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.-F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
3. L. Liu, Y. Cao, C. Chen, X. Zhang, A. McNabola, and D. Wilkie Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res 66 2006 11851 11858
4. W.J. Lee, J.L. Lee, S.E. Chang, M.W. Lee, Y.K. Kang, and J.H. Choi Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib Br J Dermatol 161 2009 1045 1051
5. C.-H. Yang, W.-C. Lin, C.-K. Chuang, Y.-C. Chang, S.-T. Pang, and Y.-C. Lin Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy Br J Dermatol 158 2008 592 596
6. S. Scholl, B. Spies-Weisshart, A. Klink, L.-O. Muegge, H.-J. Fricke, and A. Hochhaus Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations Ann Hematol 90 2011 473 475
7. K.-F. Chen, H.-L. Chen, W.-T. Tai, W.-C. Feng, C.-H. Hsu, and P.-J. Chen Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells J Pharmacol Exp Ther 2011 8
8. C. Bender, and A. Ullrich PRKX, TTBK2 and RSK4 expression causes sunitinib resistance in kidney carcinoma- and melanoma cell lines Int J Cancer 131 2011 E45 E55
9. H. Marijon, S. Dokmak, V. Paradis, M. Zappa, I. Bieche, and M. Bouattour Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma J Hepatol 54 2011 1073 1078
10. R.S. Kerbel, J. Yu, J. Tran, S. Man, A. Viloria-Petit, and G. Klement Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches Cancer Metastasis Rev 20 2001 79 86
11. W.C.M. Dempke, and V. Heinemann Resistance to EGF-R (erbB-1) and VEGF-R modulating agents Eur J Cancer 45 2009 1117 1128
12. I. Tamaskar, J. Dhillon, and R. Pili Resistance to angiogenesis inhibitors in renal cell carcinoma Clin Adv Hematol Oncol 9 2011 101 110
13. Y. Cao, W. Zhong, and Y. Sun Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance Semin Cancer Biol 19 2009 338 343
14. J.M.L. Ebos, C.R. Lee, and R.S. Kerbel Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy Clin Cancer Res 15 2009 5020 5025
15. J.M.L. Ebos, C.R. Lee, W. Cruz-Munoz, G.A. Bjarnason, J.G. Christensen, and R.S. Kerbel Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 2009 232 239
16. M. Höckel, and P. Vaupel Biological consequences of tumor hypoxia Semin Oncol 28 2001 36 41
17. C. Brahimi-Horn, and J. Pouysségur The role of the hypoxia-inducible factor in tumor metabolism growth and invasion Bull Cancer 93 2006 E73 E80
18. X. Lu, and Y. Kang Hypoxia and hypoxia-inducible factors: master regulators of metastasis Clin Cancer Res 16 2010 5928 5935
19. P. Carmeliet, L. Moons, A. Luttun, V. Vincenti, V. Compernolle, and M. De Mol Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions Nat Med 7 2001 575 583
20. A. Adini, T. Kornaga, F. Firoozbakht, and L.E. Benjamin Placental growth factor is a survival factor for tumor endothelial cells and macrophages Cancer Res 62 2002 2749 2752
21. C. Fischer, B. Jonckx, M. Mazzone, S. Zacchigna, S. Loges, and L. Pattarini Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels Cell 131 2007 463 475
22. H. Yonekura, S. Sakurai, X. Liu, H. Migita, H. Wang, and S. Yamagishi Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis J Biol Chem 274 1999 35172 35178
23. G. Alpini, S.S. Glaser, J.-P. Zhang, H. Francis, Y. Han, and J. Gong Regulation of placenta growth factor by microRNA-125b in hepatocellular cancer J Hepatol 55 2011 1339 1345
24. S.K. Selvaraj, R.K. Giri, N. Perelman, C. Johnson, P. Malik, and V.K. Kalra Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor Blood 102 2003 1515 1524
25. R.N. Kaplan, R.D. Riba, S. Zacharoulis, A.H. Bramley, L. Vincent, and C. Costa VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche Nature 438 2005 820 827
26. J.E. Park, H.H. Chen, J. Winer, K.A. Houck, and N. Ferrara Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR J Biol Chem 269 1994 25646 25654
27. C. Rolny, M. Mazzone, S. Tugues, D. Laoui, I. Johansson, and C. Coulon HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF Cancer Cell 19 2011 31 44
28. B.-Z. Qian, and J.W. Pollard Macrophage diversity enhances tumor progression and metastasis Cell 141 2010 39 51
29. S. Van de Veire, I. Stalmans, F. Heindryckx, H. Oura, A. Tijeras-Raballand, and T. Schmidt Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease Cell 141 2010 178 190
30. F. Heindryckx, I. Colle, and H. Van Vlierberghe Experimental mouse models for hepatocellular carcinoma research Int J Exp Pathol 90 2009 367 386
31. F. Heindryckx, K. Mertens, N. Charette, B. Vandeghinste, C. Casteleyn, and C. Van Steenkiste Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma Mol Cancer 9 2010 219
32. F. Heindryckx, E. Bogaerts, S.H. Coulon, H. Devlies, A.M. Geerts, and L. Libbrecht Inhibition of the placental growth factor decreases burden of cholangiocarcinoma and hepatocellular carcinoma in a transgenic mouse model Eur J Gastroenterol Hepatol 24 2012 1020 1032
33. F. Heindryckx, A. Kuchnio, C. Casteleyn, S. Coulon, K. Olievier, and I. Colle Effect of prolyl hydroxylase domain-2 haplodeficiency on hepatocarcinogenesis and progenitor cell activation J Hepatol 57 2012 61 68
34. S.K. Watkins, N.K. Egilmez, J. Suttles, and R.D. Stout IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo J Immunol 178 2007 1357 1362
35. J.W. Pollard Tumor-educated macrophages promote tumor progression and metastasis Nat Rev 4 2004 71 78
36. G.-W. Huang, L.-Y. Yang, and W.-Q. Lu Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: impact on neovascularization and survival World J Gastroenterol 11 2005 1705 1708
37. N.E. Campbell, J. Greenaway, J. Henkin, R.A. Moorehead, and J. Petrik The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer Neoplasia 12 2010 275 283
38. M.C. McGee, J.B. Hamner, R.F. Williams, S.F. Rosati, T.L. Sims, and C.Y. Ng Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation Int J Radiat Oncol 76 2010 1537 1545
39. M. Verreault, D. Strutt, D. Masin, M. Anantha, A. Yung, and P. Kozlowski Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore CTM), doxorubicin (Caelyx®) or vincristine BMC 11 2011 124
40. M. Mazzone, D. Dettori, R. Leite de Oliveira, S. Loges, T. Schmidt, and B. Jonckx Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization Cell 136 2009 839 851
41. P. Carmeliet, and R.K. Jain Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases Nat Rev 10 2011 417 427
42. S. Nagaoka, T. Yoshida, J. Akiyoshi, J. Akiba, T. Hisamoto, and Y. Yoshida The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinoma Oncol Rep 23 2010 1647 1654
43. M.-C. Ho, C.-N. Chen, H. Lee, F.-J. Hsieh, C.-T. Shun, and C.-L. Chang Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma Cancer Lett 250 2007 237 249
44. H.-X. Xu, X.-D. Zhu, P.-Y. Zhuang, J.-B. Zhang, W. Zhang, and L.-Q. Kong Expression and prognostic significance of placental growth factor in hepatocellular carcinoma and peritumoral liver tissue Int J Cancer 128 2011 1559 1569
45. Y. Yao, Y. Pan, J. Chen, X. Sun, Y. Qiu, and Y. Ding Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF Ann Clin Lab Sci 37 2007 39 48
46. C.D. Blanke Dual-antibody therapy in advanced colorectal cancer: gather ye rosebuds while ye may J Clin Oncol 27 2009 655 658
47. J.R. Hecht, E. Mitchell, T. Chidiac, C. Scroggin, C. Hagenstad, and D. Spigel A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol Soc Clin Oncol 27 2009 672 680
48. P.V. Dickson, J.B. Hamner, T.L. Sims, C.H. Fraga, C.Y.C. Ng, and S. Rajasekeran Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy Clin Caner Res 13 2007 3942 3950
49. M. Pàez-Ribes, E. Allen, J. Hudock, T. Takeda, H. Okuyama, and F. Viñals Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 2009 220 231
50. F. Winkler, S.V. Kozin, R.T. Tong, S.-S. Chae, M.F. Booth, and I. Garkavtsev Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell 6 2004 553 563